SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: glass 0.5 full11/1/2013 2:24:14 PM
  Read Replies (1) of 4474
 
So the NEJM article is available:

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Can someone let me know whether I'm missing something here -- it seems that the table enumerating "Treatment-Related Adverse Events" on page 10 doesn't have a line for any type of blood clot.

Am I reading this wrong?

They cover the SAEs for CV occlusions in the text, but do these fall under a category in the table that I'm missing?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News